Jump to section

Identification

Pharmacology

Interactions

References

Bucindolol

Enzymes (1)Biointeractions (1)

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name

Bucindolol

Accession Number

DB12752

Type

Small Molecule

Groups

Investigational

Description

Bucindolol has been investigated in Heart Failure.

Structure

Similar Structures

Synonyms

Not Available

Categories

UNII

E9UO06K7CE

CAS number

71119-11-4

Weight

Average: 363.461
Monoisotopic: 363.194677057

Chemical Formula

C₂₂H₂₅N₃O₂

InChI Key

FBMYKMYQHCBIGU-UHFFFAOYSA-N

InChI

InChI=1S/C22H25N3O2/c1-22(2,11-17-13-24-20-9-5-4-8-19(17)20)25-14-18(26)15-27-21-10-6-3-7-16(21)12-23/h3-10,13,18,24-26H,11,14-15H2,1-2H3

IUPAC Name

2-(2-hydroxy-3-{[1-(1H-indol-3-yl)-2-methylpropan-2-yl]amino}propoxy)benzonitrile

SMILES

CC(C)(CC1=CNC2=CC=CC=C12)NCC(O)COC1=CC=CC=C1C#N

Pharmacology

Indication: Not Available
Pharmacodynamics: Not Available
Mechanism of action: Not Available
Absorption: Not Available
Volume of distribution: Not Available
Protein binding: Not Available
Metabolism: Not Available
Route of elimination: Not Available
Half life: Not Available
Clearance: Not Available
Toxicity: Not Available
Affected organisms: Not Available
Pathways: Not Available
Pharmacogenomic Effects/ADRs: Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
(4R)-limonene	(4R)-limonene may decrease the antihypertensive activities of Bucindolol.	Investigational
1,10-Phenanthroline	1,10-Phenanthroline may increase the bradycardic activities of Bucindolol.	Experimental
4-Methoxyamphetamine	4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Bucindolol.	Experimental, Illicit
Acebutolol	Acebutolol may increase the orthostatic hypotensive activities of Bucindolol.	Approved, Investigational
Aceclofenac	Aceclofenac may decrease the antihypertensive activities of Bucindolol.	Approved, Investigational
Acemetacin	Acemetacin may decrease the antihypertensive activities of Bucindolol.	Approved, Experimental, Investigational
Acepromazine	Bucindolol may increase the antihypertensive activities of Acepromazine.	Approved, Vet Approved
Aceprometazine	Aceprometazine may increase the hypotensive activities of Bucindolol.	Approved
Acetohexamide	Bucindolol may increase the hypoglycemic activities of Acetohexamide.	Approved, Investigational, Withdrawn
Acetylcholine	The risk or severity of adverse effects can be increased when Bucindolol is combined with Acetylcholine.	Approved
Acetyldigitoxin	Bucindolol may increase the bradycardic activities of Acetyldigitoxin.	Approved
Acetyldigoxin	Bucindolol may increase the bradycardic activities of Acetyldigoxin.	Experimental
Acetylsalicylic acid	Acetylsalicylic acid may decrease the antihypertensive activities of Bucindolol.	Approved, Vet Approved
Adapalene	Adapalene may decrease the antihypertensive activities of Bucindolol.	Approved
Adrafinil	Bucindolol may decrease the vasoconstricting activities of Adrafinil.	Withdrawn
Agmatine	Agmatine may increase the atrioventricular blocking (AV block) activities of Bucindolol.	Experimental, Investigational
Alaproclate	The serum concentration of Bucindolol can be increased when it is combined with Alaproclate.	Experimental
Alclofenac	Alclofenac may decrease the antihypertensive activities of Bucindolol.	Approved, Withdrawn
Alfentanil	Alfentanil may increase the bradycardic activities of Bucindolol.	Approved, Illicit
Alfuzosin	Alfuzosin may increase the antihypertensive activities of Bucindolol.	Approved, Investigational
Alimemazine	Alimemazine may increase the hypotensive activities of Bucindolol.	Approved, Vet Approved
Alminoprofen	Alminoprofen may decrease the antihypertensive activities of Bucindolol.	Experimental
Alprenolol	Alprenolol may increase the orthostatic hypotensive activities of Bucindolol.	Approved, Withdrawn
Ambenonium	Ambenonium may increase the bradycardic activities of Bucindolol.	Approved
Amibegron	Bucindolol may decrease the vasoconstricting activities of Amibegron.	Investigational
Amiodarone	The therapeutic efficacy of Bucindolol can be increased when used in combination with Amiodarone.	Approved, Investigational
Amitraz	Amitraz may increase the atrioventricular blocking (AV block) activities of Bucindolol.	Vet Approved
Amitriptyline	Bucindolol may increase the antihypertensive activities of Amitriptyline.	Approved
Amlodipine	The risk or severity of hypotension can be increased when Bucindolol is combined with Amlodipine.	Approved
Amobarbital	The serum concentration of Bucindolol can be decreased when it is combined with Amobarbital.	Approved, Illicit
Amodiaquine	The metabolism of Bucindolol can be decreased when combined with Amodiaquine.	Approved, Investigational
Amoxapine	Bucindolol may increase the antihypertensive activities of Amoxapine.	Approved
Amphetamine	The risk or severity of adverse effects can be increased when Amphetamine is combined with Bucindolol.	Approved, Illicit, Investigational
Amrinone	The risk or severity of hypotension can be increased when Bucindolol is combined with Amrinone.	Approved
Andrographolide	Andrographolide may decrease the antihypertensive activities of Bucindolol.	Investigational
Anisodamine	Bucindolol may decrease the vasoconstricting activities of Anisodamine.	Investigational
Antipyrine	Antipyrine may decrease the antihypertensive activities of Bucindolol.	Approved, Investigational
Apocynin	Apocynin may decrease the antihypertensive activities of Bucindolol.	Investigational
Apomorphine	Apomorphine may increase the atrioventricular blocking (AV block) activities of Bucindolol.	Approved, Investigational
Apraclonidine	Bucindolol may decrease the vasoconstricting activities of Apraclonidine.	Approved
Apremilast	Apremilast may decrease the antihypertensive activities of Bucindolol.	Approved, Investigational
Aranidipine	The risk or severity of hypotension can be increased when Bucindolol is combined with Aranidipine.	Approved, Investigational
Arbutamine	Bucindolol may decrease the vasoconstricting activities of Arbutamine.	Approved
Arecoline	The risk or severity of adverse effects can be increased when Bucindolol is combined with Arecoline.	Experimental
Arformoterol	Bucindolol may decrease the vasoconstricting activities of Arformoterol.	Approved, Investigational
Aripiprazole	Bucindolol may increase the antihypertensive activities of Aripiprazole.	Approved, Investigational
Arotinolol	Arotinolol may increase the orthostatic hypotensive activities of Bucindolol.	Investigational
Asenapine	Bucindolol may increase the antihypertensive activities of Asenapine.	Approved
Atenolol	Atenolol may increase the orthostatic hypotensive activities of Bucindolol.	Approved
Atomoxetine	Atomoxetine may increase the hypertensive activities of Bucindolol.	Approved
Avanafil	Avanafil may increase the hypotensive activities of Bucindolol.	Approved
Azapropazone	Azapropazone may decrease the antihypertensive activities of Bucindolol.	Withdrawn
Azelastine	Azelastine may decrease the antihypertensive activities of Bucindolol.	Approved
Azelnidipine	The risk or severity of hypotension can be increased when Bucindolol is combined with Azelnidipine.	Approved, Investigational
Azimilide	The risk or severity of hypotension can be increased when Bucindolol is combined with Azimilide.	Investigational
Balsalazide	Balsalazide may decrease the antihypertensive activities of Bucindolol.	Approved, Investigational
Bambuterol	Bucindolol may decrease the vasoconstricting activities of Bambuterol.	Approved, Investigational
Barbexaclone	The serum concentration of Bucindolol can be decreased when it is combined with Barbexaclone.	Experimental
Barbital	The serum concentration of Bucindolol can be decreased when it is combined with Barbital.	Illicit
Barnidipine	The risk or severity of hypotension can be increased when Bucindolol is combined with Barnidipine.	Approved
Befunolol	Befunolol may increase the orthostatic hypotensive activities of Bucindolol.	Experimental
Bencyclane	The risk or severity of hypotension can be increased when Bucindolol is combined with Bencyclane.	Experimental
Bendazac	Bendazac may decrease the antihypertensive activities of Bucindolol.	Experimental
Benidipine	The risk or severity of hypotension can be increased when Bucindolol is combined with Benidipine.	Approved, Investigational
Benorilate	Benorilate may decrease the antihypertensive activities of Bucindolol.	Experimental
Benoxaprofen	Benoxaprofen may decrease the antihypertensive activities of Bucindolol.	Withdrawn
Benzphetamine	Benzphetamine may increase the atrioventricular blocking (AV block) activities of Bucindolol.	Approved, Illicit
Benzydamine	Benzydamine may decrease the antihypertensive activities of Bucindolol.	Approved
Bepridil	The risk or severity of hypotension can be increased when Bucindolol is combined with Bepridil.	Approved, Withdrawn
Betaxolol	Betaxolol may increase the orthostatic hypotensive activities of Bucindolol.	Approved, Investigational
Bethanechol	The risk or severity of adverse effects can be increased when Bucindolol is combined with Bethanechol.	Approved
Bethanidine	Bethanidine may increase the atrioventricular blocking (AV block) activities of Bucindolol.	Approved
Bevantolol	Bucindolol may increase the antihypertensive activities of Bevantolol.	Approved
Bevonium	Bevonium may decrease the antihypertensive activities of Bucindolol.	Experimental
Bioallethrin	The risk or severity of hypotension can be increased when Bucindolol is combined with Bioallethrin.	Approved, Experimental
Bisoprolol	Bisoprolol may increase the orthostatic hypotensive activities of Bucindolol.	Approved
Bitolterol	Bucindolol may decrease the vasoconstricting activities of Bitolterol.	Withdrawn
BL-1020	BL-1020 may increase the hypotensive activities of Bucindolol.	Investigational
Bopindolol	Bopindolol may increase the orthostatic hypotensive activities of Bucindolol.	Approved
Brexpiprazole	Bucindolol may increase the antihypertensive activities of Brexpiprazole.	Approved, Investigational
Brimonidine	Brimonidine may increase the atrioventricular blocking (AV block) activities of Bucindolol.	Approved
Bromfenac	Bromfenac may decrease the antihypertensive activities of Bucindolol.	Approved
Bromocriptine	Bromocriptine may increase the atrioventricular blocking (AV block) activities of Bucindolol.	Approved, Investigational
Bucillamine	Bucillamine may decrease the antihypertensive activities of Bucindolol.	Investigational
Bufexamac	Bufexamac may decrease the antihypertensive activities of Bucindolol.	Approved, Experimental
Bufuralol	Bufuralol may increase the orthostatic hypotensive activities of Bucindolol.	Experimental, Investigational
Bumadizone	Bumadizone may decrease the antihypertensive activities of Bucindolol.	Experimental
Bunazosin	Bunazosin may increase the antihypertensive activities of Bucindolol.	Investigational
Bupivacaine	The serum concentration of Bupivacaine can be increased when it is combined with Bucindolol.	Approved, Investigational
Bupranolol	Bupranolol may increase the orthostatic hypotensive activities of Bucindolol.	Approved
Cabergoline	Bucindolol may increase the vasoconstricting activities of Cabergoline.	Approved
Carbamoylcholine	The risk or severity of adverse effects can be increased when Bucindolol is combined with Carbachol.	Approved
Carbaspirin calcium	Carbaspirin calcium may decrease the antihypertensive activities of Bucindolol.	Experimental, Investigational
Carboxyamidotriazole	The risk or severity of hypotension can be increased when Bucindolol is combined with Carboxyamidotriazole.	Investigational
Carbutamide	Bucindolol may increase the hypoglycemic activities of Carbutamide.	Experimental
Caroverine	The risk or severity of hypotension can be increased when Bucindolol is combined with Caroverine.	Experimental
Carprofen	Carprofen may decrease the antihypertensive activities of Bucindolol.	Approved, Vet Approved, Withdrawn
Carteolol	Carteolol may increase the orthostatic hypotensive activities of Bucindolol.	Approved
Carvedilol	Carvedilol may increase the antihypertensive activities of Bucindolol.	Approved, Investigational
Castanospermine	Castanospermine may decrease the antihypertensive activities of Bucindolol.	Experimental
Celecoxib	Celecoxib may decrease the antihypertensive activities of Bucindolol.	Approved, Investigational
Celiprolol	Celiprolol may increase the orthostatic hypotensive activities of Bucindolol.	Approved, Investigational
Cevimeline	The risk or severity of adverse effects can be increased when Bucindolol is combined with Cevimeline.	Approved
Chloroquine	The metabolism of Bucindolol can be decreased when combined with Chloroquine.	Approved, Investigational, Vet Approved
Chlorphentermine	The risk or severity of adverse effects can be increased when Chlorphentermine is combined with Bucindolol.	Illicit, Withdrawn
Chlorproethazine	Chlorproethazine may increase the hypotensive activities of Bucindolol.	Experimental
Chlorpromazine	Bucindolol may increase the antihypertensive activities of Chlorpromazine.	Approved, Investigational, Vet Approved
Chlorpropamide	Bucindolol may increase the hypoglycemic activities of Chlorpropamide.	Approved, Investigational
Choline magnesium trisalicylate	Choline magnesium trisalicylate may decrease the antihypertensive activities of Bucindolol.	Approved
Cilnidipine	The risk or severity of hypotension can be increased when Bucindolol is combined with Cilnidipine.	Approved, Investigational
Cinnarizine	The risk or severity of hypotension can be increased when Bucindolol is combined with Cinnarizine.	Approved, Investigational
Cirazoline	Bucindolol may decrease the vasoconstricting activities of Cirazoline.	Experimental
Clenbuterol	The risk or severity of adverse effects can be increased when Clenbuterol is combined with Bucindolol.	Approved, Investigational, Vet Approved
Clevidipine	The risk or severity of hypotension can be increased when Bucindolol is combined with Clevidipine.	Approved, Investigational
Clonidine	Clonidine may increase the atrioventricular blocking (AV block) activities of Bucindolol.	Approved
Clonixin	Clonixin may decrease the antihypertensive activities of Bucindolol.	Approved
Cloranolol	Cloranolol may increase the orthostatic hypotensive activities of Bucindolol.	Experimental
Clozapine	Bucindolol may increase the antihypertensive activities of Clozapine.	Approved
Coumaphos	Coumaphos may increase the bradycardic activities of Bucindolol.	Vet Approved
Curcumin	Curcumin may decrease the antihypertensive activities of Bucindolol.	Approved, Investigational
Cyclandelate	The risk or severity of hypotension can be increased when Bucindolol is combined with Cyclandelate.	Approved
Cymarin	Bucindolol may increase the bradycardic activities of Cymarin.	Experimental
Dapiprazole	Bucindolol may increase the antihypertensive activities of Dapiprazole.	Approved
Dapoxetine	Dapoxetine may increase the orthostatic hypotensive activities of Bucindolol.	Investigational
Darodipine	The risk or severity of hypotension can be increased when Bucindolol is combined with Darodipine.	Experimental
Decamethonium	Decamethonium may increase the bradycardic activities of Bucindolol.	Approved
Demecarium	Demecarium may increase the bradycardic activities of Bucindolol.	Approved
Desipramine	Desipramine may increase the orthostatic hypotensive activities of Bucindolol.	Approved, Investigational
Deslanoside	Bucindolol may increase the bradycardic activities of Deslanoside.	Approved
Desvenlafaxine	The serum concentration of Bucindolol can be increased when it is combined with Desvenlafaxine.	Approved, Investigational
Detomidine	Detomidine may increase the atrioventricular blocking (AV block) activities of Bucindolol.	Vet Approved
Dexmedetomidine	Dexmedetomidine may increase the atrioventricular blocking (AV block) activities of Bucindolol.	Approved, Vet Approved
Dextroamphetamine	Bucindolol may increase the antihypertensive activities of Dextroamphetamine.	Approved, Illicit
Dichlorvos	Dichlorvos may increase the bradycardic activities of Bucindolol.	Vet Approved
Diclofenac	Diclofenac may decrease the antihypertensive activities of Bucindolol.	Approved, Vet Approved
Difenpiramide	Difenpiramide may decrease the antihypertensive activities of Bucindolol.	Experimental
Diflunisal	Diflunisal may decrease the antihypertensive activities of Bucindolol.	Approved, Investigational
Digitoxin	Bucindolol may increase the bradycardic activities of Digitoxin.	Approved, Investigational
Digoxin	Bucindolol may increase the bradycardic activities of Digoxin.	Approved
Digoxin Immune Fab (Ovine)	Bucindolol may increase the bradycardic activities of Digoxin Immune Fab (Ovine).	Approved
Dihydroergotamine	Dihydroergotamine may increase the atrioventricular blocking (AV block) activities of Bucindolol.	Approved, Investigational
Diltiazem	Diltiazem may increase the hypotensive activities of Bucindolol.	Approved, Investigational
Dipivefrin	Dipivefrin may increase the atrioventricular blocking (AV block) activities of Bucindolol.	Approved
Dipyridamole	Dipyridamole may increase the bradycardic activities of Bucindolol.	Approved
Disopyramide	Disopyramide may increase the bradycardic activities of Bucindolol.	Approved
Distigmine	Distigmine may increase the bradycardic activities of Bucindolol.	Experimental
DL-Methylephedrine	DL-Methylephedrine may increase the atrioventricular blocking (AV block) activities of Bucindolol.	Approved
Dobutamine	The risk or severity of adverse effects can be increased when Dobutamine is combined with Bucindolol.	Approved
Donepezil	Donepezil may increase the bradycardic activities of Bucindolol.	Approved
Dopamine	The risk or severity of adverse effects can be increased when Dopamine is combined with Bucindolol.	Approved
Dopexamine	Bucindolol may decrease the vasoconstricting activities of Dopexamine.	Approved, Investigational
Dotarizine	The risk or severity of hypotension can be increased when Bucindolol is combined with Dotarizine.	Investigational
Doxazosin	Doxazosin may increase the antihypertensive activities of Bucindolol.	Approved
Doxepin	Bucindolol may increase the antihypertensive activities of Doxepin.	Approved, Investigational
Doxofylline	The risk or severity of adverse effects can be increased when Bucindolol is combined with Doxofylline.	Approved, Investigational
Dronabinol	Dronabinol may increase the tachycardic activities of Bucindolol.	Approved, Illicit
Dronedarone	Dronedarone may increase the bradycardic activities of Bucindolol.	Approved
Droperidol	Bucindolol may increase the antihypertensive activities of Droperidol.	Approved, Vet Approved
Droxicam	Droxicam may decrease the antihypertensive activities of Bucindolol.	Withdrawn
Droxidopa	Droxidopa may increase the atrioventricular blocking (AV block) activities of Bucindolol.	Approved, Investigational
Duloxetine	The serum concentration of Bucindolol can be increased when it is combined with Duloxetine.	Approved
Duvelisib	Duvelisib may decrease the antihypertensive activities of Bucindolol.	Investigational
E-6201	E-6201 may decrease the antihypertensive activities of Bucindolol.	Investigational
Echothiophate	Echothiophate may increase the bradycardic activities of Bucindolol.	Approved
Edrophonium	Edrophonium may increase the bradycardic activities of Bucindolol.	Approved
Efonidipine	The risk or severity of hypotension can be increased when Bucindolol is combined with Efonidipine.	Approved, Investigational
Epanolol	Epanolol may increase the orthostatic hypotensive activities of Bucindolol.	Experimental
Eperisone	The risk or severity of hypotension can be increased when Bucindolol is combined with Eperisone.	Approved, Investigational
Ephedra	Ephedra may increase the atrioventricular blocking (AV block) activities of Bucindolol.	Approved, Nutraceutical, Withdrawn
Ephedrine	The risk or severity of adverse effects can be increased when Ephedrine is combined with Bucindolol.	Approved
Epibatidine	The risk or severity of adverse effects can be increased when Bucindolol is combined with Epibatidine.	Experimental
Epinastine	Bucindolol may decrease the vasoconstricting activities of Epinastine.	Approved, Investigational
Epinephrine	Bucindolol may increase the antihypertensive activities of Epinephrine.	Approved, Vet Approved
Epirizole	Epirizole may decrease the antihypertensive activities of Bucindolol.	Approved
Ergoloid mesylate	Bucindolol may increase the vasoconstricting activities of Ergoloid mesylate.	Approved
Ergonovine	Bucindolol may increase the vasoconstricting activities of Ergonovine.	Approved
Ergotamine	Ergotamine may increase the atrioventricular blocking (AV block) activities of Bucindolol.	Approved
Esatenolol	Esatenolol may increase the orthostatic hypotensive activities of Bucindolol.	Experimental
Escitalopram	Bucindolol may increase the antihypertensive activities of Escitalopram.	Approved, Investigational
Esmolol	Esmolol may increase the orthostatic hypotensive activities of Bucindolol.	Approved
Etafedrine	Bucindolol may decrease the vasoconstricting activities of Etafedrine.	Approved
Etanercept	Etanercept may decrease the antihypertensive activities of Bucindolol.	Approved, Investigational
Ethenzamide	Ethenzamide may decrease the antihypertensive activities of Bucindolol.	Experimental
Ethosuximide	The risk or severity of hypotension can be increased when Bucindolol is combined with Ethosuximide.	Approved
Etilefrine	The risk or severity of adverse effects can be increased when Etilefrine is combined with Bucindolol.	Withdrawn
Etodolac	Etodolac may decrease the antihypertensive activities of Bucindolol.	Approved, Investigational, Vet Approved
Etofenamate	Etofenamate may decrease the antihypertensive activities of Bucindolol.	Approved, Investigational
Etomidate	Etomidate may increase the atrioventricular blocking (AV block) activities of Bucindolol.	Approved
Etoperidone	The serum concentration of Bucindolol can be increased when it is combined with Etoperidone.	Withdrawn
Etoricoxib	Etoricoxib may decrease the antihypertensive activities of Bucindolol.	Approved, Investigational
Evening primrose oil	Evening primrose oil may decrease the antihypertensive activities of Bucindolol.	Investigational, Nutraceutical
Exisulind	Exisulind may decrease the antihypertensive activities of Bucindolol.	Investigational
Felbinac	Felbinac may decrease the antihypertensive activities of Bucindolol.	Experimental
Felodipine	The risk or severity of hypotension can be increased when Bucindolol is combined with Felodipine.	Approved, Investigational
Fenbufen	Fenbufen may decrease the antihypertensive activities of Bucindolol.	Approved
Fendiline	The risk or severity of hypotension can be increased when Bucindolol is combined with Fendiline.	Withdrawn
Fenoprofen	Fenoprofen may decrease the antihypertensive activities of Bucindolol.	Approved
Fenoterol	The risk or severity of adverse effects can be increased when Fenoterol is combined with Bucindolol.	Approved, Investigational
Fenozolone	The risk or severity of adverse effects can be increased when Bucindolol is combined with Fenozolone.	Experimental
Fentanyl	Fentanyl may increase the bradycardic activities of Bucindolol.	Approved, Illicit, Investigational, Vet Approved
Fenthion	Fenthion may increase the bradycardic activities of Bucindolol.	Vet Approved
Fentiazac	Fentiazac may decrease the antihypertensive activities of Bucindolol.	Experimental
Feprazone	Feprazone may decrease the antihypertensive activities of Bucindolol.	Experimental
Ferulic acid	Ferulic acid may decrease the antihypertensive activities of Bucindolol.	Experimental
Fingolimod	Bucindolol may increase the bradycardic activities of Fingolimod.	Approved, Investigational
Fish oil	The risk or severity of hypotension can be increased when Bucindolol is combined with Fish oil.	Approved, Nutraceutical
Floctafenine	The risk or severity of adverse effects can be increased when Bucindolol is combined with Floctafenine.	Approved, Withdrawn
Flunarizine	The risk or severity of hypotension can be increased when Bucindolol is combined with Flunarizine.	Approved
Flunixin	Flunixin may decrease the antihypertensive activities of Bucindolol.	Vet Approved
Flunoxaprofen	Flunoxaprofen may decrease the antihypertensive activities of Bucindolol.	Experimental
Fluoxetine	The serum concentration of Bucindolol can be increased when it is combined with Fluoxetine.	Approved, Vet Approved
Flupentixol	Bucindolol may increase the antihypertensive activities of Flupentixol.	Approved, Investigational, Withdrawn
Fluphenazine	Fluphenazine may increase the hypotensive activities of Bucindolol.	Approved
Flurbiprofen	Flurbiprofen may decrease the antihypertensive activities of Bucindolol.	Approved, Investigational
Fluspirilene	The risk or severity of hypotension can be increased when Bucindolol is combined with Fluspirilene.	Approved, Investigational
Formoterol	Bucindolol may decrease the vasoconstricting activities of Formoterol.	Approved, Investigational
Fostamatinib	Fostamatinib may increase the hypotensive activities of Bucindolol.	Approved, Investigational
Gabapentin	The risk or severity of hypotension can be increased when Bucindolol is combined with Gabapentin.	Approved, Investigational
Galantamine	Galantamine may increase the bradycardic activities of Bucindolol.	Approved
Gallamine Triethiodide	Gallamine Triethiodide may increase the bradycardic activities of Bucindolol.	Approved
Gallopamil	The risk or severity of hypotension can be increased when Bucindolol is combined with Gallopamil.	Investigational
Ginkgo biloba	Ginkgo biloba may increase the bradycardic activities of Bucindolol.	Approved, Investigational, Nutraceutical
Gitoformate	Bucindolol may increase the bradycardic activities of Gitoformate.	Experimental
Glibornuride	Bucindolol may increase the hypoglycemic activities of Glibornuride.	Investigational, Withdrawn
Gliclazide	Bucindolol may increase the hypoglycemic activities of Gliclazide.	Approved
Glimepiride	Bucindolol may increase the hypoglycemic activities of Glimepiride.	Approved
Glipizide	Bucindolol may increase the hypoglycemic activities of Glipizide.	Approved, Investigational
Gliquidone	Bucindolol may increase the hypoglycemic activities of Gliquidone.	Approved, Investigational
Glisoxepide	Bucindolol may increase the hypoglycemic activities of Glisoxepide.	Investigational
Glyburide	Bucindolol may increase the hypoglycemic activities of Glyburide.	Approved
GTS-21	The risk or severity of adverse effects can be increased when Bucindolol is combined with GTS-21.	Investigational
Guacetisal	Guacetisal may decrease the antihypertensive activities of Bucindolol.	Experimental
Guanabenz	Guanabenz may increase the atrioventricular blocking (AV block) activities of Bucindolol.	Approved, Investigational
Guanfacine	Guanfacine may increase the atrioventricular blocking (AV block) activities of Bucindolol.	Approved, Investigational
Hexobarbital	The serum concentration of Bucindolol can be decreased when it is combined with Hexobarbital.	Approved
Hexoprenaline	Bucindolol may decrease the vasoconstricting activities of Hexoprenaline.	Approved, Withdrawn
Higenamine	Bucindolol may decrease the vasoconstricting activities of Higenamine.	Investigational
Huperzine A	Huperzine A may increase the bradycardic activities of Bucindolol.	Approved, Investigational
Hydroxyamphetamine	The risk or severity of adverse effects can be increased when Hydroxyamphetamine is combined with Bucindolol.	Approved
Hydroxychloroquine	The metabolism of Bucindolol can be decreased when combined with Hydroxychloroquine.	Approved
Ibuprofen	Ibuprofen may decrease the antihypertensive activities of Bucindolol.	Approved
Ibuproxam	Ibuproxam may decrease the antihypertensive activities of Bucindolol.	Withdrawn
Icatibant	Icatibant may decrease the antihypertensive activities of Bucindolol.	Approved, Investigational
Iloperidone	Bucindolol may increase the antihypertensive activities of Iloperidone.	Approved
Imidazole salicylate	Imidazole salicylate may decrease the antihypertensive activities of Bucindolol.	Experimental
Imipramine	Bucindolol may increase the antihypertensive activities of Imipramine.	Approved
Indacaterol	Bucindolol may decrease the vasoconstricting activities of Indacaterol.	Approved
Indalpine	The serum concentration of Bucindolol can be increased when it is combined with Indalpine.	Investigational, Withdrawn
Indenolol	Indenolol may increase the orthostatic hypotensive activities of Bucindolol.	Withdrawn
Indobufen	Indobufen may decrease the antihypertensive activities of Bucindolol.	Investigational
Indomethacin	Indomethacin may decrease the antihypertensive activities of Bucindolol.	Approved, Investigational
Indoprofen	Indoprofen may decrease the antihypertensive activities of Bucindolol.	Withdrawn
Indoramin	Indoramin may increase the antihypertensive activities of Bucindolol.	Withdrawn
Insulin Human	Bucindolol may increase the hypoglycemic activities of Insulin Human.	Approved, Investigational
Insulin Pork	Bucindolol may increase the hypoglycemic activities of Insulin Pork.	Approved
Iobenguane	The therapeutic efficacy of Iobenguane can be decreased when used in combination with Bucindolol.	Approved, Investigational
Ipidacrine	Ipidacrine may increase the bradycardic activities of Bucindolol.	Experimental
Isoetarine	Bucindolol may decrease the vasoconstricting activities of Isoetarine.	Approved
Isoflurophate	Isoflurophate may increase the bradycardic activities of Bucindolol.	Approved, Investigational, Withdrawn
Isometheptene	Bucindolol may decrease the vasoconstricting activities of Isometheptene.	Approved
Isoprenaline	The risk or severity of adverse effects can be increased when Isoprenaline is combined with Bucindolol.	Approved, Investigational
Isoxicam	Isoxicam may decrease the antihypertensive activities of Bucindolol.	Withdrawn
Isoxsuprine	The risk or severity of adverse effects can be increased when Isoxsuprine is combined with Bucindolol.	Approved, Withdrawn
Isradipine	The risk or severity of hypotension can be increased when Bucindolol is combined with Isradipine.	Approved, Investigational
Kebuzone	Kebuzone may decrease the antihypertensive activities of Bucindolol.	Experimental
Ketoprofen	Ketoprofen may decrease the antihypertensive activities of Bucindolol.	Approved, Vet Approved
Ketorolac	Ketorolac may decrease the antihypertensive activities of Bucindolol.	Approved
Labetalol	Labetalol may increase the antihypertensive activities of Bucindolol.	Approved
Lacidipine	The risk or severity of hypotension can be increased when Bucindolol is combined with Lacidipine.	Approved, Investigational
Lamotrigine	The risk or severity of hypotension can be increased when Bucindolol is combined with Lamotrigine.	Approved, Investigational
Lanatoside C	Bucindolol may increase the bradycardic activities of Lanatoside C.	Experimental
Landiolol	Landiolol may increase the orthostatic hypotensive activities of Bucindolol.	Investigational
Leflunomide	Leflunomide may decrease the antihypertensive activities of Bucindolol.	Approved, Investigational
Lercanidipine	The risk or severity of hypotension can be increased when Bucindolol is combined with Lercanidipine.	Approved, Investigational
Levetiracetam	The risk or severity of hypotension can be increased when Bucindolol is combined with Levetiracetam.	Approved, Investigational
Levobetaxolol	Levobetaxolol may increase the orthostatic hypotensive activities of Bucindolol.	Approved, Investigational
Levomilnacipran	The serum concentration of Bucindolol can be increased when it is combined with Levomilnacipran.	Approved, Investigational
Levonordefrin	Levonordefrin may increase the atrioventricular blocking (AV block) activities of Bucindolol.	Approved
Levosalbutamol	Bucindolol may decrease the vasoconstricting activities of Levosalbutamol.	Approved, Investigational
Lidocaine	The serum concentration of Lidocaine can be increased when it is combined with Bucindolol.	Approved, Vet Approved
Lidoflazine	The risk or severity of hypotension can be increased when Bucindolol is combined with Lidoflazine.	Experimental
Linezolid	Linezolid may increase the hypertensive activities of Bucindolol.	Approved, Investigational
Lisdexamfetamine	Bucindolol may increase the antihypertensive activities of Lisdexamfetamine.	Approved, Investigational
Lisofylline	Lisofylline may decrease the antihypertensive activities of Bucindolol.	Investigational
Lobeline	The risk or severity of adverse effects can be increased when Bucindolol is combined with Lobeline.	Investigational
Lofexidine	Lofexidine may increase the atrioventricular blocking (AV block) activities of Bucindolol.	Approved, Investigational
Lonazolac	Lonazolac may decrease the antihypertensive activities of Bucindolol.	Experimental
Loperamide	The risk or severity of hypotension can be increased when Bucindolol is combined with Loperamide.	Approved
Lornoxicam	Lornoxicam may decrease the antihypertensive activities of Bucindolol.	Approved, Investigational
Loxoprofen	Loxoprofen may decrease the antihypertensive activities of Bucindolol.	Approved, Investigational
Lumiracoxib	Lumiracoxib may decrease the antihypertensive activities of Bucindolol.	Approved, Investigational
Magnesium salicylate	Magnesium salicylate may decrease the antihypertensive activities of Bucindolol.	Approved
Magnesium sulfate	The risk or severity of hypotension can be increased when Bucindolol is combined with Magnesium sulfate.	Approved, Investigational, Vet Approved
Malathion	Malathion may increase the bradycardic activities of Bucindolol.	Approved, Investigational
Manidipine	The risk or severity of hypotension can be increased when Bucindolol is combined with Manidipine.	Approved, Investigational
Masoprocol	Masoprocol may decrease the antihypertensive activities of Bucindolol.	Approved, Investigational
Meclofenamic acid	Meclofenamic acid may decrease the antihypertensive activities of Bucindolol.	Approved, Vet Approved
Medetomidine	Medetomidine may increase the atrioventricular blocking (AV block) activities of Bucindolol.	Vet Approved
Mefenamic acid	Mefenamic acid may decrease the antihypertensive activities of Bucindolol.	Approved
Mefenorex	The risk or severity of adverse effects can be increased when Bucindolol is combined with Mefenorex.	Experimental
Mefloquine	Mefloquine may increase the bradycardic activities of Bucindolol.	Approved, Investigational
Meloxicam	Meloxicam may decrease the antihypertensive activities of Bucindolol.	Approved, Vet Approved
Memantine	Memantine may increase the bradycardic activities of Bucindolol.	Approved, Investigational
Menthol	The risk or severity of hypotension can be increased when Bucindolol is combined with Menthol.	Approved
Mephentermine	Bucindolol may decrease the vasoconstricting activities of Mephentermine.	Approved
Mepindolol	Mepindolol may increase the orthostatic hypotensive activities of Bucindolol.	Experimental
Mepivacaine	The serum concentration of Mepivacaine can be increased when it is combined with Bucindolol.	Approved, Vet Approved
Mesalazine	Mesalazine may decrease the antihypertensive activities of Bucindolol.	Approved
Mesoridazine	Mesoridazine may increase the hypotensive activities of Bucindolol.	Approved, Investigational
Metahexamide	Bucindolol may increase the hypoglycemic activities of Metahexamide.	Experimental
Metamizole	Metamizole may decrease the antihypertensive activities of Bucindolol.	Approved, Investigational, Withdrawn
Metaraminol	Bucindolol may decrease the vasoconstricting activities of Metaraminol.	Approved, Investigational
Methacholine	Bucindolol may increase the bronchoconstrictory activities of Methacholine.	Approved, Investigational
Methamphetamine	Methamphetamine may increase the atrioventricular blocking (AV block) activities of Bucindolol.	Approved, Illicit
Methanesulfonyl Fluoride	Methanesulfonyl Fluoride may increase the bradycardic activities of Bucindolol.	Investigational
Methohexital	The serum concentration of Bucindolol can be decreased when it is combined with Methohexital.	Approved
Methotrimeprazine	Bucindolol may increase the antihypertensive activities of Methotrimeprazine.	Approved, Investigational
Methoxamine	Bucindolol may decrease the vasoconstricting activities of Methoxamine.	Approved, Investigational
Methoxyphenamine	Bucindolol may decrease the vasoconstricting activities of Methoxyphenamine.	Experimental
Methsuximide	The risk or severity of hypotension can be increased when Bucindolol is combined with Methsuximide.	Approved
Methyldopa	Methyldopa may increase the atrioventricular blocking (AV block) activities of Bucindolol.	Approved
Methylene blue	Methylene blue may increase the hypotensive activities of Bucindolol.	Approved, Investigational
Methylergometrine	Bucindolol may increase the vasoconstricting activities of Methylergometrine.	Approved
Methylphenobarbital	The serum concentration of Bucindolol can be decreased when it is combined with Methylphenobarbital.	Approved
Metildigoxin	Bucindolol may increase the bradycardic activities of Metildigoxin.	Experimental
Metoclopramide	Metoclopramide may increase the bradycardic activities of Bucindolol.	Approved, Investigational
Metoprolol	Metoprolol may increase the orthostatic hypotensive activities of Bucindolol.	Approved, Investigational
Mibefradil	The risk or severity of hypotension can be increased when Bucindolol is combined with Mibefradil.	Investigational, Withdrawn
Midodrine	Bucindolol may increase the bradycardic activities of Midodrine.	Approved
Milnacipran	The serum concentration of Bucindolol can be increased when it is combined with Milnacipran.	Approved, Investigational
Minaprine	Minaprine may increase the bradycardic activities of Bucindolol.	Approved
Mirabegron	Bucindolol may decrease the vasoconstricting activities of Mirabegron.	Approved
Mirodenafil	Mirodenafil may increase the hypotensive activities of Bucindolol.	Investigational
Mizoribine	Mizoribine may decrease the antihypertensive activities of Bucindolol.	Investigational
Mofebutazone	Mofebutazone may decrease the antihypertensive activities of Bucindolol.	Experimental
Moricizine	Moricizine may increase the hypotensive activities of Bucindolol.	Approved, Investigational, Withdrawn
Moxonidine	Moxonidine may increase the atrioventricular blocking (AV block) activities of Bucindolol.	Approved, Investigational
Mycophenolate mofetil	Mycophenolate mofetil may decrease the antihypertensive activities of Bucindolol.	Approved, Investigational
Mycophenolic acid	Mycophenolic acid may decrease the antihypertensive activities of Bucindolol.	Approved
Nabilone	Nabilone may increase the tachycardic activities of Bucindolol.	Approved, Investigational
Nabumetone	Nabumetone may decrease the antihypertensive activities of Bucindolol.	Approved
Nadolol	Nadolol may increase the orthostatic hypotensive activities of Bucindolol.	Approved
Nafamostat	Nafamostat may decrease the antihypertensive activities of Bucindolol.	Approved, Investigational
Naftifine	Naftifine may decrease the antihypertensive activities of Bucindolol.	Approved
Naftopidil	The risk or severity of hypotension can be increased when Bucindolol is combined with Naftopidil.	Investigational
Naphazoline	Naphazoline may increase the atrioventricular blocking (AV block) activities of Bucindolol.	Approved
Naproxen	Naproxen may decrease the antihypertensive activities of Bucindolol.	Approved, Vet Approved
Nebivolol	Nebivolol may increase the orthostatic hypotensive activities of Bucindolol.	Approved, Investigational
Nefazodone	Bucindolol may increase the antihypertensive activities of Nefazodone.	Approved, Withdrawn
Neostigmine	Neostigmine may increase the bradycardic activities of Bucindolol.	Approved, Vet Approved
Nepafenac	Nepafenac may decrease the antihypertensive activities of Bucindolol.	Approved, Investigational
Nicardipine	Bucindolol may increase the antihypertensive activities of Nicardipine.	Approved, Investigational
Nicergoline	Bucindolol may increase the antihypertensive activities of Nicergoline.	Approved, Investigational
Nicotine	The risk or severity of adverse effects can be increased when Bucindolol is combined with Nicotine.	Approved
Nifedipine	The risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Bucindolol.	Approved
Nifenazone	Nifenazone may decrease the antihypertensive activities of Bucindolol.	Experimental
Niflumic Acid	Niflumic Acid may decrease the antihypertensive activities of Bucindolol.	Approved
Niguldipine	Bucindolol may increase the antihypertensive activities of Niguldipine.	Experimental
Niludipine	The risk or severity of hypotension can be increased when Bucindolol is combined with Niludipine.	Experimental
Nilvadipine	The risk or severity of hypotension can be increased when Bucindolol is combined with Nilvadipine.	Approved, Investigational
Nimesulide	The risk or severity of hypotension can be increased when Bucindolol is combined with Nimesulide.	Approved, Investigational, Withdrawn
Nimodipine	The risk or severity of hypotension can be increased when Bucindolol is combined with Nimodipine.	Approved, Investigational
Nisoldipine	The risk or severity of hypotension can be increased when Bucindolol is combined with Nisoldipine.	Approved
Nitrendipine	The risk or severity of hypotension can be increased when Bucindolol is combined with Nitrendipine.	Approved, Investigational
Nitroaspirin	Nitroaspirin may decrease the antihypertensive activities of Bucindolol.	Investigational
Norepinephrine	Norepinephrine may increase the atrioventricular blocking (AV block) activities of Bucindolol.	Approved
Norfenefrine	Bucindolol may decrease the vasoconstricting activities of Norfenefrine.	Experimental
Nortriptyline	Bucindolol may increase the antihypertensive activities of Nortriptyline.	Approved
Nylidrin	The risk or severity of adverse effects can be increased when Nylidrin is combined with Bucindolol.	Approved
Octopamine	Bucindolol may decrease the vasoconstricting activities of Octopamine.	Experimental
Olanzapine	Bucindolol may increase the antihypertensive activities of Olanzapine.	Approved, Investigational
Oleandrin	Bucindolol may increase the bradycardic activities of Oleandrin.	Experimental, Investigational
Olodaterol	Bucindolol may decrease the vasoconstricting activities of Olodaterol.	Approved
Olopatadine	Olopatadine may decrease the antihypertensive activities of Bucindolol.	Approved
Olsalazine	Olsalazine may decrease the antihypertensive activities of Bucindolol.	Approved
Orciprenaline	The risk or severity of adverse effects can be increased when Orciprenaline is combined with Bucindolol.	Approved
Orgotein	Orgotein may decrease the antihypertensive activities of Bucindolol.	Vet Approved
Otilonium	The risk or severity of hypotension can be increased when Bucindolol is combined with Otilonium.	Experimental, Investigational
Ouabain	Bucindolol may increase the bradycardic activities of Ouabain.	Approved
Oxaprozin	Oxaprozin may decrease the antihypertensive activities of Bucindolol.	Approved
Oxprenolol	Oxprenolol may increase the orthostatic hypotensive activities of Bucindolol.	Approved
Oxyfedrine	Bucindolol may decrease the vasoconstricting activities of Oxyfedrine.	Experimental
Oxymetazoline	Oxymetazoline may increase the atrioventricular blocking (AV block) activities of Bucindolol.	Approved, Investigational
Oxyphenbutazone	Oxyphenbutazone may decrease the antihypertensive activities of Bucindolol.	Approved, Withdrawn
Paliperidone	Bucindolol may increase the antihypertensive activities of Paliperidone.	Approved
Palmidrol	Palmidrol may decrease the antihypertensive activities of Bucindolol.	Experimental, Nutraceutical
Paraoxon	Paraoxon may increase the bradycardic activities of Bucindolol.	Experimental
Parecoxib	Parecoxib may decrease the antihypertensive activities of Bucindolol.	Approved
Paroxetine	The serum concentration of Bucindolol can be increased when it is combined with Paroxetine.	Approved, Investigational
Parthenolide	Parthenolide may decrease the antihypertensive activities of Bucindolol.	Approved, Investigational
Penbutolol	Penbutolol may increase the orthostatic hypotensive activities of Bucindolol.	Approved, Investigational
Pentobarbital	The serum concentration of Bucindolol can be decreased when it is combined with Pentobarbital.	Approved, Investigational, Vet Approved
Pentoxifylline	Pentoxifylline may increase the hypotensive activities of Bucindolol.	Approved, Investigational
Perazine	Perazine may increase the hypotensive activities of Bucindolol.	Approved, Investigational
Pergolide	Pergolide may increase the atrioventricular blocking (AV block) activities of Bucindolol.	Approved, Investigational, Vet Approved, Withdrawn
Perphenazine	Perphenazine may increase the hypotensive activities of Bucindolol.	Approved
Peruvoside	Bucindolol may increase the bradycardic activities of Peruvoside.	Experimental
Phendimetrazine	Bucindolol may decrease the vasoconstricting activities of Phendimetrazine.	Approved, Illicit
Phenmetrazine	The risk or severity of adverse effects can be increased when Phenmetrazine is combined with Bucindolol.	Approved, Illicit
Phenobarbital	The serum concentration of Bucindolol can be decreased when it is combined with Phenobarbital.	Approved, Investigational
Phenoxybenzamine	Bucindolol may increase the antihypertensive activities of Phenoxybenzamine.	Approved
Phentermine	The risk or severity of adverse effects can be increased when Phentermine is combined with Bucindolol.	Approved, Illicit
Phentolamine	Bucindolol may increase the antihypertensive activities of Phentolamine.	Approved
Phenylbutazone	Phenylbutazone may decrease the antihypertensive activities of Bucindolol.	Approved, Vet Approved
Phenylephrine	Bucindolol may decrease the vasoconstricting activities of Phenylephrine.	Approved
Phenylpropanolamine	The risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Bucindolol.	Approved, Vet Approved, Withdrawn
Physostigmine	Physostigmine may increase the bradycardic activities of Bucindolol.	Approved, Investigational
Pilocarpine	The risk or severity of adverse effects can be increased when Bucindolol is combined with Pilocarpine.	Approved, Investigational
Pimecrolimus	Pimecrolimus may decrease the antihypertensive activities of Bucindolol.	Approved, Investigational
Pinaverium	The risk or severity of hypotension can be increased when Bucindolol is combined with Pinaverium.	Approved
Pindolol	Pindolol may increase the orthostatic hypotensive activities of Bucindolol.	Approved, Investigational
Pirbuterol	Bucindolol may decrease the vasoconstricting activities of Pirbuterol.	Approved
Pirfenidone	Pirfenidone may decrease the antihypertensive activities of Bucindolol.	Approved, Investigational
Piroxicam	Piroxicam may decrease the antihypertensive activities of Bucindolol.	Approved, Investigational
Pirprofen	Pirprofen may decrease the antihypertensive activities of Bucindolol.	Experimental
Pizotifen	Bucindolol may increase the antihypertensive activities of Pizotifen.	Approved
Platelet Activating Factor	Platelet Activating Factor may increase the orthostatic hypotensive activities of Bucindolol.	Experimental
Practolol	Practolol may increase the orthostatic hypotensive activities of Bucindolol.	Approved
Pranoprofen	Pranoprofen may decrease the antihypertensive activities of Bucindolol.	Experimental, Investigational
Prazosin	Prazosin may increase the antihypertensive activities of Bucindolol.	Approved
Prenalterol	The risk or severity of adverse effects can be increased when Bucindolol is combined with Prenalterol.	Experimental
Prenylamine	The risk or severity of hypotension can be increased when Bucindolol is combined with Prenylamine.	Withdrawn
Primaquine	The metabolism of Bucindolol can be decreased when combined with Primaquine.	Approved
Primidone	The serum concentration of Bucindolol can be decreased when it is combined with Primidone.	Approved, Vet Approved
Procaterol	The risk or severity of adverse effects can be increased when Procaterol is combined with Bucindolol.	Approved, Investigational
Prochlorperazine	Prochlorperazine may increase the hypotensive activities of Bucindolol.	Approved, Vet Approved
Proglumetacin	Proglumetacin may decrease the antihypertensive activities of Bucindolol.	Experimental
Promazine	Bucindolol may increase the antihypertensive activities of Promazine.	Approved, Vet Approved
Promethazine	Promethazine may increase the hypotensive activities of Bucindolol.	Approved, Investigational
Propacetamol	Propacetamol may decrease the antihypertensive activities of Bucindolol.	Approved, Investigational
Propafenone	The serum concentration of Bucindolol can be increased when it is combined with Propafenone.	Approved
Propericiazine	Bucindolol may increase the antihypertensive activities of Propericiazine.	Approved, Investigational
Propiomazine	Bucindolol may increase the antihypertensive activities of Propiomazine.	Approved
Propiopromazine	Propiopromazine may increase the hypotensive activities of Bucindolol.	Vet Approved
Propiverine	Bucindolol may increase the antihypertensive activities of Propiverine.	Approved, Investigational
Propranolol	Propranolol may increase the orthostatic hypotensive activities of Bucindolol.	Approved, Investigational
Propyphenazone	Propyphenazone may decrease the antihypertensive activities of Bucindolol.	Experimental
Proquazone	Proquazone may decrease the antihypertensive activities of Bucindolol.	Experimental
Proscillaridin	Bucindolol may increase the bradycardic activities of Proscillaridin.	Experimental
Protokylol	Bucindolol may decrease the vasoconstricting activities of Protokylol.	Approved, Vet Approved
Pseudoephedrine	Pseudoephedrine may increase the atrioventricular blocking (AV block) activities of Bucindolol.	Approved
PTC299	PTC299 may decrease the antihypertensive activities of Bucindolol.	Investigational
Pyridostigmine	Pyridostigmine may increase the bradycardic activities of Bucindolol.	Approved, Investigational
Quetiapine	Bucindolol may increase the antihypertensive activities of Quetiapine.	Approved
Quinidine	Bucindolol may increase the antihypertensive activities of Quinidine.	Approved, Investigational
Racepinephrine	Bucindolol may increase the antihypertensive activities of Racepinephrine.	Approved
Ractopamine	Bucindolol may decrease the vasoconstricting activities of Ractopamine.	Vet Approved
Regorafenib	Regorafenib may increase the bradycardic activities of Bucindolol.	Approved
Remifentanil	Remifentanil may increase the bradycardic activities of Bucindolol.	Approved
Reproterol	Bucindolol may decrease the vasoconstricting activities of Reproterol.	Investigational
Reserpine	Reserpine may increase the hypotensive activities of Bucindolol.	Approved, Investigational
Resveratrol	Resveratrol may decrease the antihypertensive activities of Bucindolol.	Approved, Experimental, Investigational
Rifampicin	The serum concentration of Bucindolol can be decreased when it is combined with Rifampicin.	Approved
Rifapentine	The serum concentration of Bucindolol can be decreased when it is combined with Rifapentine.	Approved, Investigational
Rifaximin	The serum concentration of Bucindolol can be decreased when it is combined with Rifaximin.	Approved, Investigational
Rilmenidine	Bucindolol may decrease the vasoconstricting activities of Rilmenidine.	Approved, Investigational
Rimiterol	Bucindolol may decrease the vasoconstricting activities of Rimiterol.	Experimental
Risperidone	Bucindolol may increase the antihypertensive activities of Risperidone.	Approved, Investigational
Ritobegron	Bucindolol may decrease the vasoconstricting activities of Ritobegron.	Investigational
Ritodrine	The risk or severity of adverse effects can be increased when Ritodrine is combined with Bucindolol.	Approved, Investigational
Rivastigmine	Bucindolol may increase the bradycardic activities of Rivastigmine.	Approved, Investigational
Rofecoxib	Rofecoxib may decrease the antihypertensive activities of Bucindolol.	Approved, Investigational, Withdrawn
Romifidine	Romifidine may increase the atrioventricular blocking (AV block) activities of Bucindolol.	Vet Approved
Ropinirole	Ropinirole may increase the atrioventricular blocking (AV block) activities of Bucindolol.	Approved, Investigational
Salbutamol	Bucindolol may decrease the vasoconstricting activities of Salbutamol.	Approved, Vet Approved
Salicylamide	Salicylamide may decrease the antihypertensive activities of Bucindolol.	Approved
Salicylic acid	Salicylic acid may decrease the antihypertensive activities of Bucindolol.	Approved, Investigational, Vet Approved
Salmeterol	Bucindolol may decrease the vasoconstricting activities of Salmeterol.	Approved
Salsalate	Salsalate may decrease the antihypertensive activities of Bucindolol.	Approved
Secobarbital	The serum concentration of Bucindolol can be decreased when it is combined with Secobarbital.	Approved, Vet Approved
Seletracetam	The risk or severity of hypotension can be increased when Bucindolol is combined with Seletracetam.	Investigational
Semapimod	Semapimod may decrease the antihypertensive activities of Bucindolol.	Investigational
Seratrodast	Seratrodast may decrease the antihypertensive activities of Bucindolol.	Approved
Serrapeptase	Serrapeptase may decrease the antihypertensive activities of Bucindolol.	Investigational
Sertraline	The serum concentration of Bucindolol can be increased when it is combined with Sertraline.	Approved
Sildenafil	Sildenafil may increase the hypotensive activities of Bucindolol.	Approved, Investigational
Silodosin	Silodosin may increase the antihypertensive activities of Bucindolol.	Approved
Solabegron	Bucindolol may decrease the vasoconstricting activities of Solabegron.	Investigational
Sotalol	Sotalol may increase the orthostatic hypotensive activities of Bucindolol.	Approved
SRT501	SRT501 may decrease the antihypertensive activities of Bucindolol.	Investigational
Sufentanil	Sufentanil may increase the bradycardic activities of Bucindolol.	Approved, Investigational
Sulfasalazine	Sulfasalazine may decrease the antihypertensive activities of Bucindolol.	Approved
Sulindac	Sulindac may decrease the antihypertensive activities of Bucindolol.	Approved, Investigational
Suprofen	Suprofen may decrease the antihypertensive activities of Bucindolol.	Approved, Withdrawn
Suxibuzone	Suxibuzone may decrease the antihypertensive activities of Bucindolol.	Experimental
Synephrine	The risk or severity of adverse effects can be increased when Synephrine is combined with Bucindolol.	Experimental
Tacrine	Tacrine may increase the bradycardic activities of Bucindolol.	Investigational, Withdrawn
Tadalafil	Tadalafil may increase the hypotensive activities of Bucindolol.	Approved, Investigational
Tafenoquine	The metabolism of Bucindolol can be decreased when combined with Tafenoquine.	Approved, Investigational
Talinolol	Talinolol may increase the orthostatic hypotensive activities of Bucindolol.	Investigational
Tamsulosin	Tamsulosin may increase the antihypertensive activities of Bucindolol.	Approved, Investigational
Tarenflurbil	Tarenflurbil may decrease the antihypertensive activities of Bucindolol.	Investigational
Tedizolid phosphate	Tedizolid Phosphate may increase the hypertensive activities of Bucindolol.	Approved
Tenidap	Tenidap may decrease the antihypertensive activities of Bucindolol.	Experimental
Tenoxicam	Tenoxicam may decrease the antihypertensive activities of Bucindolol.	Approved
Tepoxalin	Tepoxalin may decrease the antihypertensive activities of Bucindolol.	Vet Approved
Terazosin	Terazosin may increase the antihypertensive activities of Bucindolol.	Approved
Terbutaline	Terbutaline may increase the orthostatic hypotensive activities of Bucindolol.	Approved
Teriflunomide	Teriflunomide may decrease the antihypertensive activities of Bucindolol.	Approved
Terodiline	The risk or severity of hypotension can be increased when Bucindolol is combined with Terodiline.	Experimental
Tertatolol	Tertatolol may increase the orthostatic hypotensive activities of Bucindolol.	Experimental
Tetrahydropalmatine	The risk or severity of hypotension can be increased when Bucindolol is combined with Tetrahydropalmatine.	Investigational
Tetryzoline	The risk or severity of adverse effects can be increased when Tetryzoline is combined with Bucindolol.	Approved
Theophylline	Theophylline may increase the hypotensive activities of Bucindolol.	Approved
Thiamylal	The serum concentration of Bucindolol can be decreased when it is combined with Thiamylal.	Approved, Vet Approved
Thiazinam	Thiazinam may increase the hypotensive activities of Bucindolol.	Experimental
Thiethylperazine	Thiethylperazine may increase the hypotensive activities of Bucindolol.	Withdrawn
Thiopental	The serum concentration of Bucindolol can be decreased when it is combined with Thiopental.	Approved, Vet Approved
Thioproperazine	Bucindolol may increase the antihypertensive activities of Thioproperazine.	Approved
Thioridazine	Bucindolol may increase the antihypertensive activities of Thioridazine.	Approved, Withdrawn
Tiaprofenic acid	Tiaprofenic acid may decrease the antihypertensive activities of Bucindolol.	Approved
Timolol	Timolol may increase the orthostatic hypotensive activities of Bucindolol.	Approved
Tinoridine	Tinoridine may decrease the antihypertensive activities of Bucindolol.	Investigational
Tizanidine	Tizanidine may increase the atrioventricular blocking (AV block) activities of Bucindolol.	Approved, Investigational
Tolazamide	Bucindolol may increase the hypoglycemic activities of Tolazamide.	Approved, Investigational
Tolazoline	Bucindolol may increase the antihypertensive activities of Tolazoline.	Approved, Vet Approved
Tolbutamide	Bucindolol may increase the hypoglycemic activities of Tolbutamide.	Approved, Investigational
Tolfenamic Acid	The risk or severity of hypotension can be increased when Bucindolol is combined with Tolfenamic Acid.	Approved, Investigational
Tolmetin	Tolmetin may decrease the antihypertensive activities of Bucindolol.	Approved
Tramazoline	The risk or severity of adverse effects can be increased when Bucindolol is combined with Tramazoline.	Investigational
Tranilast	The risk or severity of hypotension can be increased when Bucindolol is combined with Tranilast.	Approved, Investigational
Trazodone	Bucindolol may increase the antihypertensive activities of Trazodone.	Approved, Investigational
Tretoquinol	The risk or severity of adverse effects can be increased when Bucindolol is combined with Tretoquinol.	Experimental
Tribenoside	Tribenoside may decrease the antihypertensive activities of Bucindolol.	Experimental
Trichlorfon	Trichlorfon may increase the bradycardic activities of Bucindolol.	Vet Approved
Trifluoperazine	Bucindolol may increase the antihypertensive activities of Trifluoperazine.	Approved, Investigational
Triflupromazine	Triflupromazine may increase the hypotensive activities of Bucindolol.	Approved, Vet Approved
Trimazosin	Trimazosin may increase the antihypertensive activities of Bucindolol.	Experimental
Trimebutine	The risk or severity of hypotension can be increased when Bucindolol is combined with Trimebutine.	Approved
Trimethadione	The risk or severity of hypotension can be increased when Bucindolol is combined with Trimethadione.	Approved
Trimipramine	Bucindolol may increase the antihypertensive activities of Trimipramine.	Approved
Triptolide	Triptolide may decrease the antihypertensive activities of Bucindolol.	Investigational
Tubocurarine	Tubocurarine may increase the bradycardic activities of Bucindolol.	Approved
Tulobuterol	Bucindolol may decrease the vasoconstricting activities of Tulobuterol.	Investigational
Tyramine	The risk or severity of adverse effects can be increased when Tyramine is combined with Bucindolol.	Investigational, Nutraceutical
Tyrothricin	Tyrothricin may increase the bradycardic activities of Bucindolol.	Approved
Udenafil	Udenafil may increase the hypotensive activities of Bucindolol.	Approved, Investigational
Urapidil	Urapidil may increase the antihypertensive activities of Bucindolol.	Investigational
Valdecoxib	Valdecoxib may decrease the antihypertensive activities of Bucindolol.	Approved, Investigational, Withdrawn
Vardenafil	Vardenafil may increase the hypotensive activities of Bucindolol.	Approved
Varenicline	The risk or severity of adverse effects can be increased when Bucindolol is combined with Varenicline.	Approved, Investigational
Venlafaxine	The serum concentration of Bucindolol can be increased when it is combined with Venlafaxine.	Approved
Verapamil	Bucindolol may increase the antihypertensive activities of Verapamil.	Approved
Vilanterol	Bucindolol may decrease the vasoconstricting activities of Vilanterol.	Approved
Vinpocetine	The risk or severity of hypotension can be increased when Bucindolol is combined with Vinpocetine.	Investigational
WIN 55212-2	The risk or severity of hypotension can be increased when Bucindolol is combined with WIN 55212-2.	Experimental
Xamoterol	Bucindolol may decrease the vasoconstricting activities of Xamoterol.	Experimental
Xylazine	Xylazine may increase the atrioventricular blocking (AV block) activities of Bucindolol.	Vet Approved
Xylometazoline	Xylometazoline may increase the atrioventricular blocking (AV block) activities of Bucindolol.	Approved, Investigational
Zaltoprofen	Zaltoprofen may decrease the antihypertensive activities of Bucindolol.	Approved, Investigational
Ziconotide	The risk or severity of hypotension can be increased when Bucindolol is combined with Ziconotide.	Approved
Zileuton	Zileuton may decrease the antihypertensive activities of Bucindolol.	Approved, Investigational, Withdrawn
Zimelidine	The serum concentration of Bucindolol can be increased when it is combined with Zimelidine.	Withdrawn
Ziprasidone	Bucindolol may increase the antihypertensive activities of Ziprasidone.	Approved
Zomepirac	Zomepirac may decrease the antihypertensive activities of Bucindolol.	Withdrawn
Zonisamide	The risk or severity of hypotension can be increased when Bucindolol is combined with Zonisamide.	Approved, Investigational
Zuclopenthixol	Bucindolol may increase the antihypertensive activities of Zuclopenthixol.	Approved, Investigational

Food Interactions

Not Available

References

General References

Not Available

External Links

PubChem Compound: 51045
PubChem Substance: 347828941
ChemSpider: 46266
BindingDB: 50169808
ChEMBL: CHEMBL321582
PharmGKB: PA165945764
Wikipedia: Bucindolol

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
2	Completed	Treatment	Current or Recent History of Atrial Fibrillation	1
Not Available	Unknown Status	Not Available	Heart Failure, Unspecified	1

Pharmacoeconomics

Manufacturers: Not Available
Packagers: Not Available
Dosage forms: Not Available
Prices: Not Available
Patents: Not Available

Properties

State

Not Available

Experimental Properties

Not Available

Predicted Properties

Property	Value	Source
Water Solubility	0.00744 mg/mL	ALOGPS
logP	3.4	ALOGPS
logP	3.49	ChemAxon
logS	-4.7	ALOGPS
pKa (Strongest Acidic)	14.09	ChemAxon
pKa (Strongest Basic)	9.69	ChemAxon
Physiological Charge	1	ChemAxon
Hydrogen Acceptor Count	4	ChemAxon
Hydrogen Donor Count	3	ChemAxon
Polar Surface Area	81.07 Å²	ChemAxon
Rotatable Bond Count	8	ChemAxon
Refractivity	106.44 m³·mol^-1	ChemAxon
Polarizability	39.98 Å³	ChemAxon
Number of Rings	3	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	Yes	ChemAxon

Predicted ADMET features

Not Available

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	Not Available

Taxonomy

Description: This compound belongs to the class of organic compounds known as 3-alkylindoles. These are compounds containing an indole moiety that carries an alkyl chain at the 3-position.
Kingdom: Organic compounds
Super Class: Organoheterocyclic compounds
Class: Indoles and derivatives
Sub Class: Indoles
Direct Parent: 3-alkylindoles
Alternative Parents: Phenoxy compounds / Phenol ethers / Benzonitriles / Aralkylamines / Alkyl aryl ethers / Substituted pyrroles / Heteroaromatic compounds / Secondary alcohols / 1,2-aminoalcohols / Nitriles
show 4 more
Substituents: 3-alkylindole / Phenoxy compound / Benzonitrile / Phenol ether / Alkyl aryl ether / Aralkylamine / Monocyclic benzene moiety / Benzenoid / Substituted pyrrole / Heteroaromatic compound
show 18 more
Molecular Framework: Aromatic heteropolycyclic compounds
External Descriptors: Not Available

Enzymes

Details1. Cytochrome P450 2D6

Kind: Protein
Organism: Human
Pharmacological action: No
Actions: Substrate

General Function: Steroid hydroxylase activity
Specific Function: Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name: CYP2D6
Uniprot ID: P10635
Uniprot Name: Cytochrome P450 2D6
Molecular Weight: 55768.94 Da

References

Sternieri E, Coccia CP, Pinetti D, Guerzoni S, Ferrari A: Pharmacokinetics and interactions of headache medications, part II: prophylactic treatments. Expert Opin Drug Metab Toxicol. 2006 Dec;2(6):981-1007. doi: 10.1517/17425255.2.6.981 . [PubMed:17125412]
Brodde OE, Kroemer HK: Drug-drug interactions of beta-adrenoceptor blockers. Arzneimittelforschung. 2003;53(12):814-22. [PubMed:14732961]
Iwaki M, Niwa T, Bandoh S, Itoh M, Hirose H, Kawase A, Komura H: Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432. doi: 10.1016/j.dmpk.2016.08.007. Epub 2016 Sep 2. [PubMed:27836712]

Drug created on October 20, 2016 18:01 / Updated on August 02, 2018 06:43

Bucindolol

Identification

Structure for DB12752 (Bucindolol)

Pharmacology

Interactions

References

Clinical Trials

Pharmacoeconomics

Properties

Spectra

Taxonomy

Enzymes

References